Cigogne Management SA Invests $1.17 Million in Inhibrx, Inc. (NASDAQ:INBX)

Cigogne Management SA acquired a new position in shares of Inhibrx, Inc. (NASDAQ:INBX - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 75,932 shares of the company's stock, valued at approximately $1,169,000. Cigogne Management SA owned approximately 0.52% of Inhibrx at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. PNC Financial Services Group Inc. purchased a new stake in Inhibrx during the 4th quarter worth about $28,000. Natixis purchased a new stake in Inhibrx during the 4th quarter worth about $31,000. JPMorgan Chase & Co. increased its position in Inhibrx by 47.8% during the 4th quarter. JPMorgan Chase & Co. now owns 7,592 shares of the company's stock worth $117,000 after purchasing an additional 2,457 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in Inhibrx during the 4th quarter worth about $47,000. Finally, New York State Common Retirement Fund purchased a new stake in Inhibrx during the 4th quarter worth about $53,000. Hedge funds and other institutional investors own 82.46% of the company's stock.

Inhibrx Stock Performance

INBX stock traded down $0.70 on Tuesday, hitting $11.66. 149,196 shares of the company were exchanged, compared to its average volume of 197,353. Inhibrx, Inc. has a twelve month low of $10.80 and a twelve month high of $34.75. The business's fifty day moving average is $13.00 and its two-hundred day moving average is $14.03.

Inhibrx (NASDAQ:INBX - Get Free Report) last issued its quarterly earnings results on Monday, March 17th. The company reported ($3.09) EPS for the quarter, missing the consensus estimate of ($2.88) by ($0.21). The company had revenue of $0.10 million for the quarter. Sell-side analysts anticipate that Inhibrx, Inc. will post 104.88 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, JMP Securities reaffirmed a "market perform" rating on shares of Inhibrx in a research note on Wednesday, January 22nd.

Inhibrx Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.